pemetrexed and Leukemia--Lymphoid

pemetrexed has been researched along with Leukemia--Lymphoid* in 1 studies

Other Studies

1 other study(ies) available for pemetrexed and Leukemia--Lymphoid

Article	Year
A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. Journal of medicinal chemistry, 1992, Nov-13, Volume: 35, Issue:23 N-[4-[2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid (15), prepared in five steps from 2-pivaloyl-7-deazaguanine, has been found to be an antitumor agent with its primary site of action at thymidylate synthase rather than purine synthesis. This compound appears to be a promising candidate for clinical evaluation. Topics: Animals; Antineoplastic Agents; Glutamates; Guanine; Humans; Leukemia L1210; Leukemia, Lymphoid; Mice; Pemetrexed; Structure-Activity Relationship; Thymidylate Synthase; Tumor Cells, Cultured	1992

Article

Year

A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase.

Journal of medicinal chemistry, 1992, Nov-13, Volume: 35, Issue:23

N-[4-[2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid (15), prepared in five steps from 2-pivaloyl-7-deazaguanine, has been found to be an antitumor agent with its primary site of action at thymidylate synthase rather than purine synthesis. This compound appears to be a promising candidate for clinical evaluation.

Topics: Animals; Antineoplastic Agents; Glutamates; Guanine; Humans; Leukemia L1210; Leukemia, Lymphoid; Mice; Pemetrexed; Structure-Activity Relationship; Thymidylate Synthase; Tumor Cells, Cultured

1992